REPL Stock Jumps As FDA Panel Backs Melanoma Drug

Positive trial updates for Replimune Group Inc. could further extend its rally, as stocks have been trading up by 132.9 percent

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading REPL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Replimune’s melanoma therapy RP1 plus nivolumab won a favorable 10–3 vote from the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee on its IGNYTE trial efficacy data.
The panel’s conclusion supports Replimune Group Inc.’s ongoing BLA resubmission for RP1 in advanced melanoma ahead of an August 2, 2026 PDUFA decision date.
A 10–3 vote in favor of REPL’s experimental melanoma treatment signals a constructive regulatory stance and higher odds of eventual FDA approval.
Wedbush had expected the panel to call RP1’s data clinically meaningful, but it kept a Neutral rating and $9 price target on REPL, citing caution around near-term approval.

Quick Financial Overview

REPL is trading like a classic biotech volatility play. In mid-July, Replimune Group Inc. sat comfortably around $11–$11.50. Then the stock slid hard, dropping from $10.99 on 2026/07/10 to $5.41 by 2026/07/29–2026/07/30. That’s a brutal cut in market value in just a few weeks, even by small-cap biotech standards.

The intraday tape tells a different story now. Around the FDA news, REPL has ripped back into the low $12s, with heavy premarket swings between roughly $11.20 and $13.00. That kind of whipsaw action is what momentum traders live for, but it demands tight risk control.

More Breaking News

On the fundamentals, Replimune Group Inc. remains a development-stage name. The latest quarter shows a net loss of about $73.2M and negative EBITDA of roughly $69.0M. Cash and equivalents sit at about $209.0M, with total liquidity (including short-term investments) near $268.9M, giving REPL a runway but not a free pass. A current ratio of 4.8 and low near-term debt pressures help, yet returns on equity and assets are deeply negative. For traders, REPL is a high-risk, binary-outcome biotech where regulatory catalysts matter far more than current earnings.

Why Traders Are Watching REPL After The FDA Vote

Traders are locked in on Replimune Group Inc. because the story just flipped from pure uncertainty to a more defined regulatory setup. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 that RP1 plus nivolumab showed evaluable and clinically meaningful efficacy in the single-arm IGNYTE study for advanced melanoma. For a small-cap like REPL, that kind of panel backing is a major de-risking moment.

Here’s why it matters. Before this week, the RP1 program carried a cloud: criticism of the trial design, questions about single-arm data, and debate over how much each drug contributed to the effect. Wedbush even highlighted those concerns while still predicting the data would be called clinically meaningful, and it kept a Neutral rating and $9 target on REPL. That cautious stance helped push sentiment down and contributed to the slide from double digits to the mid-single digits.

Now the tone is different. The advisory committee essentially told the market that, yes, the data are good enough to seriously support a biologics license application. That doesn’t guarantee approval, but it changes the probabilities. For REPL, the August 2, 2026 PDUFA date becomes a hard catalyst that traders can anchor to. Between now and that date, every pullback in Replimune Group Inc. will be judged against the odds that RP1 in combination with nivolumab actually reaches the market. This is why you’re seeing REPL spike intraday from around $11 to near $13 on volume — shorts are reassessing, and momentum traders are piling in around the catalyst.

Conclusion

For active traders, REPL is now a classic “event-driven biotech” chart. Replimune Group Inc. went from a slow bleed under $6 back to a fast-moving $12–$13 tape on the back of one key vote. The 10–3 advisory committee decision in favor of RP1’s melanoma data gives the company something it didn’t have last week: credible external validation that the IGNYTE results matter clinically and are fit to support the BLA resubmission.

That said, the game is not over. The FDA still has the final word, and Wedbush’s Neutral rating and $9 target show that not everyone is ready to price in a clean approval path. REPL still burns cash, still posts wide quarterly losses, and still depends heavily on future regulatory success. Any negative update between now and the 2026/08/02 PDUFA date can hit the stock hard.

This is where process matters. As Tim Sykes loves to remind traders, “The market doesn’t care about your opinion, only your plan and your risk.” And as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” Both principles underscore that REPL is a ticker where preparation, planning, and disciplined execution matter more than any single headline. For REPL, that means treating every move as a trading opportunity, not a promise. Define your risk, respect the volatility, and let the price action around Replimune Group Inc.’s catalysts guide your decisions. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!